Eric P Krenning
Overview
Explore the profile of Eric P Krenning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
6654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bibika M, Kanellopoulos P, Rouchota M, Loudos G, Nock B, Krenning E, et al.
Pharmaceutics
. 2024 Sep;
16(9).
PMID: 39339259
The concept of radiotheranostics relies on the overexpression of a biomolecular target on malignant cells to direct diagnostic/therapeutic radionuclide-carriers specifically to cancer lesions. The concomitant expression of more than one...
2.
Tatsi A, Maina T, Waser B, Krenning E, de Jong M, Reubi J, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38339198
The overexpression of one or more somatostatin receptors (SSTR) in human tumors has provided an opportunity for diagnosis and therapy with somatostatin-like radionuclide carriers. The application of "pansomatostatin" analogs is...
3.
Kanellopoulos P, Nock B, Rouchota M, Loudos G, Krenning E, Maina T
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958525
Radiolabeled neurotensin analogs have been developed as candidates for theranostic use against neurotensin subtype 1 receptor (NTSR)-expressing cancer. However, their fast degradation by two major peptidases, neprilysin (NEP) and angiotensin-converting...
4.
Kanellopoulos P, Nock B, Krenning E, Maina T
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631306
The neurotensin subtype 1 receptor (NTSR) is overexpressed in a number of human tumors, thereby representing a valid target for cancer theranostics with radiolabeled neurotensin (NT) analogs like [Tc]Tc-DT1 (DT1,...
5.
Nock B, Kanellopoulos P, Chepurny O, Rouchota M, Loudos G, Holz G, et al.
Pharmaceutics
. 2022 Mar;
14(3).
PMID: 35336041
(1) Background: Theranostic approaches in the management of cholecystokinin subtype 2 receptor (CCKR)-positive tumors include radiolabeled gastrin and CCK motifs. Moving toward antagonist-based CCKR-radioligands instead, we herein present three analogs...
6.
Strosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, et al.
Lancet Oncol
. 2021 Nov;
22(12):1752-1763.
PMID: 34793718
Background: The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced...
7.
Hasan D, Shono A, van Kalken C, van der Spek P, Krenning E, Kotani T
Purinergic Signal
. 2021 Nov;
18(1):13-59.
PMID: 34757513
Hyperinflammation plays an important role in severe and critical COVID-19. Using inconsistent criteria, many researchers define hyperinflammation as a form of very severe inflammation with cytokine storm. Therefore, COVID-19 patients...
8.
Hicks R, Dromain C, de Herder W, Costa F, Deroose C, Frilling A, et al.
J Neuroendocrinol
. 2021 Oct;
34(3):e13040.
PMID: 34668262
The European Neuroendocrine Tumor Society (ENETS) promotes practices and procedures that aim to improve the standard of care delivered to patients diagnosed with or suspected of having neuroendocrine neoplasia (NEN)....
9.
Strosberg J, Srirajaskanthan R, El-Haddad G, Wolin E, Chasen B, Kulke M, et al.
J Nucl Med
. 2021 Mar;
PMID: 33771903
We report the impact of Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. All patients enrolled in...
10.
Kanellopoulos P, Kaloudi A, Rouchota M, Loudos G, de Jong M, Krenning E, et al.
Pharmaceutics
. 2020 Dec;
12(12).
PMID: 33256013
Background: Peptide radioligands may serve as radionuclide carriers to tumor sites overexpressing their cognate receptor for diagnostic or therapeutic purposes. Treatment of mice with the neprilysin (NEP)-inhibitor phosphoramidon was previously...